Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease

NCT00004408 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Anemia

Interventions

DRUG: poloxamer 188

Sponsor

Mast Therapeutics, Inc.

Collaborators

[object Object]